Michael Klichinsky Sells 165,000 Shares of Carisma Therapeutics (NASDAQ:CARM) Stock

Carisma Therapeutics Inc. (NASDAQ:CARM) insider Michael Klichinsky sold 165,000 shares of the company’s stock in a transaction dated Wednesday, October 1st. The shares were sold at an average price of $0.26, for a total value of $42,900.00. Following the transaction, the insider directly owned 319,347 shares in the company, valued at $83,030.22. This represents a 34.07% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Michael Klichinsky also recently made the following trade(s):

• On Friday, October 3rd, Michael Klichinsky sold 119,347 shares of Carisma Therapeutics stock. The shares were sold at an average price of $0.26, for a total value of $31,030.22.
• On Thursday, October 2nd, Michael Klichinsky sold 200,000 shares of Carisma Therapeutics stock. The stock was sold at an average price of $0.25, for a total value of $50,000.00.

Carisma Therapeutics Stock Down 3.4%

CARM opened at $0.26 on Friday. The company has a market cap of $10.90 million, a P/E ratio of -0.17 and a beta of 2.06. The firm’s 50-day moving average price is $0.30 and its 200-day moving average price is $0.30. Carisma Therapeutics Inc. has a 52-week low of $0.14 and a 52-week high of $1.27.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on CARM shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Carisma Therapeutics in a report on Saturday, September 27th. Evercore ISI upgraded Carisma Therapeutics to a “strong-buy” rating in a research note on Tuesday, July 15th. Finally, D. Boral Capital reaffirmed a “buy” rating and set a $1.00 price target on shares of Carisma Therapeutics in a research report on Friday, August 8th. Two equities research analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $1.93.

Institutional Investors Weigh In On Carisma Therapeutics

An institutional investor recently bought a new position in Carisma Therapeutics stock. Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in Carisma Therapeutics Inc. (NASDAQ:CARM) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 200,000 shares of the company’s stock, valued at approximately $62,000. Universal Beteiligungs und Servicegesellschaft mbH owned approximately 0.48% of Carisma Therapeutics as of its most recent filing with the Securities and Exchange Commission. 44.27% of the stock is owned by institutional investors.

About Carisma Therapeutics

Carisma Therapeutics, Inc, a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others.